Last reviewed · How we verify

severe alopecia areata — Treatment Landscape & Competitive Intelligence

severe alopecia areata (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating severe alopecia areata, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Leqselvi DEURUXOLITINIB Sun Pharm Inds Inc JAK1, JAK2, TYK2 2024-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Sun Pharm Inds Inc · 1 drug in severe alopecia areata

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in severe alopecia areata:

Cite this brief

Drug Landscape (2026). severe alopecia areata — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/severe-alopecia-areata. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing